companydata.dkcompanydata.dk

AVP BioPharma Consult ApS: Financial statements 2025

CVR: 37770426

Source: annual report 2025, Danish Business Authority

01/01/2025 – 31/12/2025

AVP BioPharma Consult ApS (CVR 37770426) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK 1,249,151 and a net result of DKK 247,464 compared with DKK 237,789 the year before. That is an increase of 6.8% compared with the year before. Equity in the 2025 report amounted to DKK 320,541. The solvency ratio was 72.2%. The company had 1 employee in the financial year.

Gross Profit
DKK 1,249,151
Profit/Loss
DKK 247,464
Equity
DKK 320,541
Total Assets
DKK 444,014
Employees
1

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2025-1.2M247K321K1
2024-1.2M238K323K1
2023-1M106K225K1
2022-1.1M148K294K1
2021-1.2M261K346K1

Official annual report

View the official annual report directly on the page with a Pro subscription.

How creditworthy is AVP BioPharma Consult ApS?

See the CDS score and get a full credit report with recommended credit limit and payment terms.

Read about the CDS score

Events in 2025

AVP BioPharma Consult ApS: The 2024 annual report is outMar 1, 2025

AVP BioPharma Consult ApS has published its annual report for 2024. Gross profit came to DKK 1,169,184, and the net result was DKK 237,789.

About AVP BioPharma Consult ApS

AVP BioPharma Consult ApS is a Danish company of the type Anpartsselskab based in Virum, founded in 2016. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Anders Vagnø Pedersen. The company is owned by AVP Holdings ApS. The company has 1 employee (2026). In 2025, the company reported a gross profit of DKK 1,249,151 and a net result of DKK 247,464 compared with DKK 237,789 the year before. Equity in the 2025 report amounted to DKK 320,541.

Source: annual report 2025, Danish Business Authority